MedTrace Logo

Long-term Safety and Tolerability of BHV-7000

NCT06443463 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 660

Last updated 2026-05-01

No results posted yet for this study

Summary

A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy

Conditions

  • Focal Epilepsy

Interventions

DRUG

BHV-7000

BHV-7000 50 mg. Participants will take open-label investigational product (IP) once daily

DRUG

BHV-7000

BHV-7000 75 mg. Participants will take open-label investigational product (IP) once daily

Sponsors & Collaborators

  • Biohaven Therapeutics Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-30
Primary Completion
2026-12-31
Completion
2027-01-31
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Austria
  • Belgium
  • Chile
  • Croatia
  • Czechia
  • Denmark
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • India
  • Italy
  • Mexico
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06443463 on ClinicalTrials.gov